Photo by P Virot, WHO
Abu Dhabi Grants US$ 25 million to Global Malaria Partnership
9 February 2010, Geneva, Switzerland - The Government of Abu Dhabi announced today a grant of US$25 million, over five years, to support the work of the Roll Back Malaria Partnership (RBM). Specifically to scale-up malaria control worldwide and contribute to achieving the United Nations Millennium Development Goals (MDG) by 2015.
Read RBM Press Release [in English], [in French]
Partners meet to set 2010 global malaria advocacy agenda
8 February 2010, Geneva, Switzerland - More than 40 RBM Partners met in Geneva for the Fifth Annual Meeting of the Malaria Advocacy Working Group (MAWG) to assess key international advocacy opportunities in 2010. Participants focussed on RBM Workplan targets and deliverables and tailored malaria messages to target audiences in recipient and donor countries.
Read provisional agenda
More than 2 billion people at risk of P.Vivax malaria in 2009
29-31 January 2010, Shanghai, PR China - Scientists from 11 countries, members of the Asia and Pacific Region P.Vivax knowledge-sharing network, gathered today to work on a common operational agenda for research and development policy to improve the effectiveness of control interventions against malaria caused by Plasmodium vivax.
Convened by the National Institute of Parasitic Diseases, CDC, China PR & National Institute of Infectious Diseases, Japan, the meeting called attention to the increasing frequency and severity of P.vivax malaria worldwide.
Controlling and eliminating P.Vivax malaria is one of the biggest challenges for achieving the ambitious targets, outlined in the Global Malaria Action Plan (GMAP). Global estimates of morbidity related to P.Vivax malaria infection and relapse ranges between 70-80 million cases annually. The direct economic impact of P.Vivax malaria is significant as the disease affects adult, economically active populations in some of the world largest economies.
While important gains are being made in controlling the life-threatening P.falciparum malaria, research and development for P.Vivax control and elimination has been neglected for many decades.
To help advance research on P.Vivax in the Asia-Pacific Region, the RBM Partnership Secretariat highlighted two important RBM frameworks for research development at today's scientific meeting - the overall research agenda, outlined in the GMAP and the Malaria Eradication Research Agenda (malERA).
To view more on Partnership activities visit RBM Events archive and RBM Calendar of Events